Krebs Biochemicals Industries Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Krebs Biochemicals & Industries Ltd is ₹ 57.85 as of 15 May 15:30 . The P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 years The Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 174.33 crore on March 2021 to ₹ 144 crore on March 2025 . This represents a CAGR of -3.75% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 years The revenue of Krebs Biochemicals & Industries Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 7.28 crore. This represent the decline of -100% The revenue of Novartis India Ltd for the Mar '26 is ₹ 100.56 crore as compare to the Dec '25 revenue of ₹ 94.65 crore. This represent the growth of 6.24% The ebitda of Krebs Biochemicals & Industries Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0.3 crore. This represent the decline of -100% The ebitda of Novartis India Ltd for the Mar '26 is ₹ 30.63 crore as compare to the Dec '25 ebitda of ₹ 31.11 crore. This represent the decline of -1.54% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ -5.17 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 25.25 crore over 8 quarters. This represents a CAGR of -0.96% The Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Krebs Biochemicals & Industries Ltd and Novartis India Ltd

Which company has a larger market capitalization, Krebs Biochemicals & Industries Ltd or Novartis India Ltd?

Market cap of Krebs Biochemicals & Industries Ltd is 120 Cr while Market cap of Novartis India Ltd is 2,914 Cr

What are the key factors driving the stock performance of Krebs Biochemicals & Industries Ltd and Novartis India Ltd?

The stock performance of Krebs Biochemicals & Industries Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Krebs Biochemicals & Industries Ltd and Novartis India Ltd?

As of May 18, 2026, the Krebs Biochemicals & Industries Ltd stock price is INR ₹55.71. On the other hand, Novartis India Ltd stock price is INR ₹1180.5.

How do dividend payouts of Krebs Biochemicals & Industries Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Krebs Biochemicals & Industries Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.